Spinal muscular atrophy (SMA) is a prevalent paediatric neuromuscular disorder characterised by muscle weakness and atrophy resulting from degeneration of spinal cord anterior horn ± motor neurons. Gene therapy formulations exhibit varying bene ts and limitations, driving the need for patient-friendly treatment options tailored to speci c populations. The objective of this meta-analysis was to assess the e ectiveness of gene therapy for motor function in children with SMA. The analysis encompassed a total of 719 participants from six randomised controlled trials (RCTs) conducted between 2017 and 2023. Among the studies, one demonstrated a signi cant and large standardised e ect size (Cohen'sd) favouring nusinersen in terms oHfammersmith Functional Motor Scale Expanded (HFMSE) (d = 0.97) and revised upper limb module (RULM) (d = 0.96). Additionally, another study showed a moderate standardised e ect size (Cohen's d) in favour of nusinersen concerning Hammersmith Infant Neurological Examination-Section 2 (HINE-2) (d = 0.48). However, it is important to note that further research with a longer duration of observation is required to strengthen the evidence.